Orell-Kotikangas Helena, Österlund Pia, Mäkitie Outi, Saarilahti Kauko, Ravasco Paula, Schwab Ursula, Mäkitie Antti A
a Department of Clinical Nutrition Therapy , Helsinki University Hospital , Helsinki , Finland.
b Department of Oncology , University of Helsinki and Helsinki University Hospital , Helsinki , Finland.
Acta Otolaryngol. 2017 Jul;137(7):778-785. doi: 10.1080/00016489.2016.1277263. Epub 2017 Jan 26.
One third of the patients had cachexia with an association of significantly shorter survival. These results suggest that combining HGS and MAMA seems to be a practical method to screen cachexia in patients with head and neck cancer and may also be used when assessing their prognosis.
The aim of this study was to analyze the hypothesis that cachexia defined as both low mid-arm muscle area (MAMA) and handgrip strength (HGS) is associated with decreased survival in patients with head and neck squamous cell carcinoma (HNSCC).
Sixty-five consecutive patients with primary HNSCC were enrolled prior to cancer therapy. Cachexia was defined as low handgrip strength (HGS) and low mid-arm muscle area (MAMA). Nutritional status was assessed by patient-generated subjective global assessment (PG-SGA) and sarcopenia by low MAMA. Biochemical parameters reflecting nutritional status and S-25-OHD were measured.
Cachexia was seen in 31% and sarcopenia in 46% of patients. Altogether, 34% of patients were malnourished. Disease-free survival was 13 months (3-62) in cachectic patients, compared with 66 months (31-78) in non-cachectic patients (p = 0.009). S-25-OHD was 28 nmol/l in cachectic patients, compared with 46 nmol/l in non-cachectic patients (p = 0.009) and prealbumin 187 mg/l and 269 mg/l, respectively (p < 0.001).
三分之一的患者存在恶病质,且生存期明显缩短。这些结果表明,联合使用握力(HGS)和上臂中部肌肉面积(MAMA)似乎是筛查头颈癌患者恶病质的实用方法,也可用于评估其预后。
本研究旨在分析以下假设,即定义为低上臂中部肌肉面积(MAMA)和握力(HGS)的恶病质与头颈部鳞状细胞癌(HNSCC)患者生存率降低相关。
65例原发性HNSCC患者在癌症治疗前入组。恶病质定义为低握力(HGS)和低上臂中部肌肉面积(MAMA)。通过患者主观全面评定法(PG-SGA)评估营养状况,通过低MAMA评估肌肉减少症。测量反映营养状况和S-25-OHD的生化参数。
31%的患者出现恶病质,46%的患者出现肌肉减少症。共有34%的患者营养不良。恶病质患者的无病生存期为13个月(3 - 62个月),而非恶病质患者为66个月(31 - 78个月)(p = 0.009)。恶病质患者的S-25-OHD为28 nmol/l,非恶病质患者为46 nmol/l(p = 0.009),前白蛋白分别为187 mg/l和269 mg/l(p < 0.001)。